Pharmaceutical companies have stepped up pressure on the Government to push back against proposed new regulations of the sector, which pharma giant Pfizer privately warned could damage the Irish ...

Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

The company also reaffirmed its guidance for the remainder of the year, emphasizing its strategic focus on research and development along with operational efficiencies. Pfizer reported revenues of $13 ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational relationships; ...

Pfizer Inc. PFE will release earnings results ... Readers can sort by stock ticker, company name, analyst firm, rating change or other variables. Let's have a look at how Benzinga's most-accurate ...